Altea gains US grant for pain relief patch:
This article was originally published in Clinica
Executive Summary
Altea Development has received a phase I grant from the US National Institutes of Health (NIH) to develop its skin patch for the delivery of opioid pain medications. The micropore opioid patch is intended initially to provide continuous opioid delivery throughout the day and subsequently for patient-controlled, on-demand delivery for treating more severe pain, says the Atlanta, Georgia company. The system may benefit in particular those patients for whom oral drugs are ineffective or in cases where injections and infusion pumps are impractical, the firm adds.